Janus Henderson Group PLC Design Therapeutics, Inc. Transaction History

Janus Henderson Group PLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$4.99 - $7.64 $71,322 - $109,198	-14,293 Reduced 1.69%	829,425 $5.23 Million
Q1 2023 May 15, 2023	SELL	$5.5 - $9.77 $1.44 Million - $2.56 Million	-262,141 Reduced 23.7%	843,718 $4.87 Million
Q4 2022 Feb 14, 2023	SELL	$7.86 - $17.2 $3.13 Million - $6.84 Million	-397,952 Reduced 26.46%	1,105,859 $11.3 Million
Q3 2022 Nov 14, 2022	BUY	$14.09 - $25.57 $5.93 Million - $10.8 Million	420,971 Added 38.88%	1,503,811 $25.1 Million
Q2 2022 Aug 15, 2022	SELL	$9.91 - $17.33 $353,896 - $618,871	-35,711 Reduced 3.19%	1,082,840 $15.2 Million
Q1 2022 May 16, 2022	BUY	$11.17 - $20.89 $2.03 Million - $3.8 Million	181,784 Added 19.41%	1,118,551 $18.1 Million
Q4 2021 Feb 14, 2022	BUY	$13.64 - $21.41 $1,473 - $2,312	108 Added 0.01%	936,767 $19.1 Million
Q3 2021 Nov 16, 2021	BUY	$13.99 - $20.03 $125 - $180	9 Added 0.0%	936,659 $13.1 Million
Q2 2021 Aug 16, 2021	SELL	$19.02 - $29.78 $4.75 Million - $7.44 Million	-249,986 Reduced 21.07%	936,650 $17.7 Million
Q1 2021 May 17, 2021	BUY	$29.52 - $41.49 $35 Million - $49.2 Million	1,186,636 New	1,186,636 $32.7 Million

102

31M

2.3K

16.5K

Ticker DSGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,807,900
Market Cap $252M
Description
Design Therapeutics, Inc. a preclinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of genetic diseases caused by nucleotide repeat expansions. The company's portfolio of products comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ syste...

Get notified when there are updates to the investment portfolio of Janus Henderson Group PLC, based on Form 13F filings with the SEC.

Stay updated on Janus Henderson Group PLC with notifications on news.